26.97
-1.60 (-5.60%)
| Penutupan Terdahulu | 28.57 |
| Buka | 27.44 |
| Jumlah Dagangan | 2,129,839 |
| Purata Dagangan (3B) | 1,629,123 |
| Modal Pasaran | 3,303,614,208 |
| Harga / Pendapatan (P/E Ke hadapan) | 126.58 |
| Harga / Jualan (P/S) | 7.70 |
| Harga / Buku (P/B) | 14.89 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2026 |
| Margin Keuntungan | -60.95% |
| Margin Operasi (TTM) | -37.25% |
| EPS Cair (TTM) | -1.04 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 32.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 77.67% |
| Nisbah Semasa (MRQ) | 3.55 |
| Aliran Tunai Operasi (OCF TTM) | -110.94 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -66.54 M |
| Pulangan Atas Aset (ROA TTM) | -18.43% |
| Pulangan Atas Ekuiti (ROE TTM) | -70.57% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Arcutis Biotherapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -3.5 |
| Purata | -0.70 |
|
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.95% |
| % Dimiliki oleh Institusi | 108.79% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 36.00 (Needham, 33.48%) | Beli |
| Median | 35.00 (29.77%) | |
| Rendah | 34.00 (HC Wainwright & Co., 26.07%) | Beli |
| Purata | 35.00 (29.77%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 27.49 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Mizuho | 02 Mar 2026 | 35.00 (29.77%) | Beli | 24.76 |
| Guggenheim | 27 Feb 2026 | 35.00 (29.77%) | Beli | 26.97 |
| HC Wainwright & Co. | 26 Feb 2026 | 34.00 (26.07%) | Beli | 28.57 |
| Needham | 26 Feb 2026 | 36.00 (33.48%) | Beli | 28.57 |
| 26 Jan 2026 | 31.00 (14.94%) | Beli | 26.32 | |
| TD Cowen | 26 Feb 2026 | 35.00 (29.77%) | Beli | 28.57 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |